Miao Zhao

Miao Zhao

Auto-generated profile, based on publicly available information

Miao Zhao

Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2020 in Science
Verified
Journal Article
Closed access
PDF file
FZFan Zhang
Fan Zhang
MZMiao Zhao
Miao Zhao
DBDoug R. Braun
Doug R. Braun
SESpencer Snyder Ericksen
Spencer Snyder Ericksen
JPJeff S. Piotrowski
Jeff S. Piotrowski
TBTim S. Bugni
Tim S. Bugni
Prospecting for antifungal molecules: Marine bacteria produce a plethora of natural products that often have unusual chemical structures and corresponding reactivity, which sometimes translate into a valuable biological function. Zhang et al. used a metabolomic screen to zero in on microbial strains from the microbiome of a sea squirt that produces a high diversity of chemical structures. They then screened these molecules for inhibition of fungi (see the Perspective by Cowen). A polycyclic molecule dubbed turbinmicin possessed potent antifungal activity against the multidrug-resistant fungal pathogens Candida auris and Aspergillus fumigatus . Preliminary mechanism-of-action and mouse toxicity studies suggest that this molecule works though a fungus-specific pathway and is well tolerated at therapeutic doses. Science , this issue p. 974 ; see also p. 906

1 March 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MZMiao Zhao
Miao Zhao
FZFan Zhang
Fan Zhang
RZRobert Zarnowski
Robert Zarnowski
KBKenneth Barns
Kenneth Barns
RJRyley Jones
Ryley Jones
DADavid Andes
David Andes
The emergence of drug-resistant fungi has prompted an urgent threat alert from the US Centers for Disease Control (CDC). Biofilm assembly by these pathogens further impairs effective therapy. We recently identified an antifungal, turbinmicin, that inhibits the fungal vesicle–mediated trafficking pathway and demonstrates broad-spectrum activity against planktonically growing fungi. During biofilm growth, vesicles with unique features play a critical role in the delivery of biofilm extracellular matrix components. As these components are largely responsible for the drug resistance associated with biofilm growth, we explored the utility of turbinmicin in the biofilm setting. We found that turbinmicin disrupted extracellular vesicle (EV) delivery during biofilm growth and that this impaired the subsequent assembly of the biofilm matrix. We demonstrated that elimination of the extracellular matrix rendered the drug-resistant biofilm communities susceptible to fungal killing by turbinmicin. Furthermore, the addition of turbinmicin to otherwise ineffective antifungal therapy potentiated the activity of these drugs. The underlying role of vesicles explains this dramatic activity and was supported by phenotype reversal with the addition of exogenous biofilm EVs. This striking capacity to cripple biofilm assembly mechanisms reveals a new approach to eradicating biofilms and sheds light on turbinmicin as a promising anti-biofilm drug.

1 December 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ALAlexander J. Lepak
Alexander J. Lepak
MZMiao Zhao
Miao Zhao
DADavid Andes
David Andes
WCK 5222 is a combination of cefepime and the novel β-lactam enhancer (BLE) zidebactam. Zidebactam has a dual mechanism of action involving high-affinity penicillin binding protein 2 (PBP2) binding as well as inhibition of Ambler class A and C enzymes. In the current study, we evaluated the effect of zidebactam on the cefepime pharmacodynamic parameter target time above MIC (T>MIC) exposure required for efficacy against a diverse group of carbapenem-resistant Enterobacteriaceae (CRE) strains secondary to metallo-β-lactamase (MBL) production. Plasma and epithelial lining fluid (ELF) pharmacokinetic (PK) studies were performed for both cefepime (6.25, 25, and 100 mg/kg of body weight) and zidebactam (3.125, 12.5, and 50 mg/kg) after subcutaneous administration to mice. Only total drug was considered protein binding is MIC. The results were modeled to evaluate the relationship between the cefepime T>MIC (when zidebactam was coadministered) and therapeutic effect. The results revealed a strong association between T>MIC and effect (R2 = 0.82). Net stasis in organism burden occurred at cefepime T>MIC exposures of only 18%. A 1-log kill endpoint was demonstrated for the group of organisms at approximately 31% T>MIC. These target exposures for stasis and 1-log kill are much lower than previously observed cephalosporin monotherapy PK/PD targets.

1 November 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
ALAlexander J. Lepak
Alexander J. Lepak
MZMiao Zhao
Miao Zhao
DADavid Andes
David Andes
Rezafungin (CD101) is a novel echinocandin under development for once-weekly intravenous (i.v.) dosing. We evaluated the pharmacodynamics (PD) of rezafungin against 4 Candida tropicalis and 4 Candida dubliniensis strains, using the neutropenic mouse invasive candidiasis model. The area under the concentration-time curve (AUC)/MIC was a robust predictor of efficacy ( R 2 = 0.93 and 0.72, respectively).

8 June 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SGShruti U. Gandhy
Shruti U. Gandhy
SCSandra J. Casak
Sandra J. Casak
SMSirisha L. Mushti
Sirisha L. Mushti
JCJoyce Cheng
Joyce Cheng
SSSriram Subramaniam
Sriram Subramaniam
LFLola A. Fashoyin-Aje
Lola A. Fashoyin-Aje
On September 30, 2022, the FDA granted accelerated approval to futibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions or other rearrangements. Approval was based on Study TAS-120–101, a multicenter open-label, single-arm trial. Patients received futibatinib 20-mg orally once daily. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DoR) as determined by an independent review committee (IRC) according to RECIST v1.1. ORR was 42% (95% confidence interval, 32%–52%). Median DoR was 9.7 months. Adverse reactions occurring in ≥30% patients were nail toxicity, musculoskeletal pain, constipation, diarrhea, fatigue, dry mouth, alopecia, stomatitis, and abdominal pain. The most common laboratory abnormalities (≥50%) were increased phosphate, increased creatinine, decreased hemoglobin, and increased glucose. Ocular toxicity (including dry eye, keratitis, and retinal epithelial detachment) and hyperphosphatemia are important risks of futibatinib, which are listed under Warnings and Precautions. This article summarizes the FDA's thought process and data supporting the approval of futibatinib.

1 July 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ALAlexander J. Lepak
Alexander J. Lepak
MZMiao Zhao
Miao Zhao
DADavid Andes
David Andes
The pharmacodynamics of telavancin and vancomycin were compared using neutropenic murine thigh and lung infection models. Four Staphylococcus aureus strains were included. The telavancin MIC ranged from 0.06 to 0.25 mg/liter, and the vancomycin MIC ranged from 1 to 4 mg/liter. The plasma pharmacokinetics of escalating doses (1.25, 5, 20, and 80 mg/kg of body weight) of telavancin and vancomycin were linear over the dose range. Epithelial lining fluid (ELF) pharmacokinetics for each drug revealed that penetration into the ELF mirrored the percentage of the free fraction (the fraction not protein bound) in plasma for each drug. Telavancin (0.3125 to 80 mg/kg/6 h) and vancomycin (0.3125 to 1,280 mg/kg/6 h) were administered by the subcutaneous route in treatment studies. Dose-dependent bactericidal activity against all four strains was observed in both models. A sigmoid maximum-effect model was used to determine the area under the concentration-time curve (AUC)/MIC exposure associated with net stasis and 1-log 10 kill relative to the burden at the start of therapy. The 24-h plasma free drug AUC ( f AUC)/MIC values associated with stasis and 1-log kill were remarkably congruent. Net stasis for telavancin was noted at f AUC/MIC values of 83 and 40.4 in the thigh and lung, respectively, and 1-log kill was noted at f AUC/MIC values of 215 and 76.4, respectively. For vancomycin, the f AUC/MIC values for stasis were 77.9 and 45.3, respectively, and those for 1-log kill were 282 and 113, respectively. The 24-h ELF total drug AUC/MIC targets in the lung model were very similar to the 24-h plasma free drug AUC/MIC targets for each drug. Integration of human pharmacokinetic data for telavancin, the results of the MIC distribution studies, and the pharmacodynamic targets identified in this study suggests that the current dosing regimen of telavancin is optimized to obtain drug exposures sufficient to treat S. aureus infections.